Difference between revisions of "Part:BBa K3846350:Design"

(→‎Source)
(→‎Source)
 
Line 13: Line 13:
  
 
Optimization of the mevalonate-based isoprenoid biosynthetic pathway in Escherichia coli for production of the anti-malarial drug precursor amorpha-4,11-diene. Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD. Metab Eng. 2009 Jan;11(1):13-9. doi: 10.1016/j.ymben.2008.07.007. Epub 2008 Aug 12. 10.1016/j.ymben.2008.07.007
 
Optimization of the mevalonate-based isoprenoid biosynthetic pathway in Escherichia coli for production of the anti-malarial drug precursor amorpha-4,11-diene. Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD. Metab Eng. 2009 Jan;11(1):13-9. doi: 10.1016/j.ymben.2008.07.007. Epub 2008 Aug 12. 10.1016/j.ymben.2008.07.007
 +
 +
[https://www.addgene.org/100167/]
 +
[https://www.addgene.org/100169/]
  
 
===References===
 
===References===

Latest revision as of 10:54, 20 October 2021


MevT pathway


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

based on studies conducted by J. Keasling et al..

Source

Optimization of the mevalonate-based isoprenoid biosynthetic pathway in Escherichia coli for production of the anti-malarial drug precursor amorpha-4,11-diene. Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD. Metab Eng. 2009 Jan;11(1):13-9. doi: 10.1016/j.ymben.2008.07.007. Epub 2008 Aug 12. 10.1016/j.ymben.2008.07.007

[1] [2]

References